Zhu ZF - Search Results

1

Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay.

Li XL, Liu JY, Lu R, Xu Q, Zhu ZF, Wang L, Zhou CL, Jia J, Fu Z, Yao Z. Li XL, et al. Among authors: zhu zf. Invest New Drugs. 2008 Dec;26(6):525-9. doi: 10.1007/s10637-008-9121-8. Epub 2008 Feb 9. Invest New Drugs. 2008. PMID: 18264678

2

Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.

Zhao L, Zhao Q, Lu R, Fu Z, Zhu Z, Jia J, Wang S, Shi L, Jian X, Yao Z. Zhao L, et al. J Cell Biochem. 2008 Feb 1;103(2):471-8. doi: 10.1002/jcb.21409. J Cell Biochem. 2008. PMID: 17546603

3

Tyroservatide therapy for tumor invasion and metastasis of human ovarian carcinoma and colon carcinoma.

Wang L, Che X, Li X, Lv J, Zhou C, Wang S, Zhu Z, Wang L, Lin G, Lu R, Yao Z. Wang L, et al. Anticancer Drugs. 2012 Nov;23(10):1067-77. doi: 10.1097/CAD.0b013e328357bd31. Anticancer Drugs. 2012. PMID: 22922208

4

Effects of Tyroserleutide on phosphatidylinositol 3'-kinase/AKT pathway in human hepatocellular carcinoma cell.

Fu Z, Ren L, Wei H, Lv J, Che X, Zhu Z, Jia J, Wang L, Lin G, Lu R, Yao Z. Fu Z, et al. J Drug Target. 2014 Feb;22(2):146-55. doi: 10.3109/1061186X.2013.844820. Epub 2013 Oct 23. J Drug Target. 2014. PMID: 24147456

5

Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell.

Yao Z, Che XC, Lu R, Zheng MN, Zhu ZF, Li JP, Jian X, Shi LX, Liu JY, Gao WY. Yao Z, et al. Among authors: zhu zf. Mol Med. 2007 Jan-Feb;13(1-2):14-21. doi: 10.2119/2006-00061.Yao. Mol Med. 2007. PMID: 17515953 Free PMC article.

6

Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU.

Shi LX, Ma R, Lu R, Xu Q, Zhu ZF, Wang L, Zhou CL, Li XL, Zhang HL, Yao Z. Shi LX, et al. Among authors: zhu zf. Cancer Lett. 2008 Sep 28;269(1):101-10. doi: 10.1016/j.canlet.2008.04.033. Epub 2008 Jun 5. Cancer Lett. 2008. PMID: 18538471

7

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation.

Zhu ZF, Chen LJ, Lu R, Jia J, Liang Y, Xu Q, Zhou CL, Wang L, Wang S, Yao Z. Zhu ZF, et al. BMC Cancer. 2008 Nov 25;8:342. doi: 10.1186/1471-2407-8-342. BMC Cancer. 2008. PMID: 19025669 Free PMC article.

8

[Evaluation of the inhibitory effect of tripeptide tyroservatide on growth of human hepatocellular carcinoma using a hollow fiber assay].

Shi LX, Lu R, Wang L, Zhou CL, Xu Q, Zhu ZF, Ma R, Zhang HL, Jia J, Fu Z, Yao Z. Shi LX, et al. Among authors: zhu zf. Zhonghua Zhong Liu Za Zhi. 2008 Oct;30(10):725-8. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173797 Chinese.

9

Effects of a novel tripeptide, tyroserleutide (YSL), on cell cycle progression of human hepatocellular carcinoma.

Wang C, Wang S, Lu R, Zhao L, Zhu ZF, Xu Q, Lv JQ, Wang LL, Fu Z, Lin G, Yao Z. Wang C, et al. Among authors: zhu zf. Anticancer Drugs. 2009 Aug;20(7):534-42. doi: 10.1097/CAD.0b013e32832ced93. Anticancer Drugs. 2009. PMID: 19491661

10

Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9.

Che X, Lu R, Fu Z, Sun Y, Zhu ZF, Li JP, Wang S, Jia J, Wang Q, Yao Z. Che X, et al. Among authors: zhu zf. Drug Des Devel Ther. 2018 Oct 9;12:3357-3368. doi: 10.2147/DDDT.S177126. eCollection 2018. Drug Des Devel Ther. 2018. Retraction in: Drug Des Devel Ther. 2023 Feb 28;17:647-648. doi: 10.2147/DDDT.S409954 PMID: 30349190 Free PMC article. Retracted.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters